Impact of Complete Revascularization on Development of Heart Failure in Patients With Acute Coronary Syndrome and Multivessel Disease: A Subanalysis of the CORALYS Registry
Authors: Bruno Francesco , Marengo Giorgio , De Filippo Ovidio , Wanha Wojciech , Leonardi Sergio , Raposeiras Roubin Sergio , Fabris Enrico , Popovic Maja , Giannino Giuseppe , Truffa Alessandra , Huczek Zenon , Gaibazzi Nicola , Ielasi Alfonso , Cortese Bernardo , Borin Andrea , Núñez‐Gil Iván J. , Melis Daniele , Ugo Fabrizio , Bianco Matteo , Barbieri Lucia , Marchini Federico , Desperak Piotr , Montalto Claudio , Melendo‐Viu Maria , Elia Edoardo , Mancone Massimo , Buono Andrea , Ferrandez‐Escarabajal Marcos , Morici Nuccia , Scaglione Marco , Tuttolomondo Domenico , Sardella Gennaro , Gasior Mariusz , Mazurek Maciej , Gallone Guglielmo , Pagliaro Beniamino , Lopiano Clara , Campo Gianluca , Wojakowski Wojciech , Abu‐Assi Emad , Sinagra Gianfranco , De Ferrari Gaetano Maria , D'Ascenzo Fabrizio ,   Collaborators
Published: July 2023

Background

The impact of complete revascularization (CR) on the development of heart failure (HF) in patients with acute coronary syndrome and multivessel coronary artery disease undergoing percutaneous coronary intervention remains to be elucidated.

Methods and Results

Consecutive patients with acute coronary syndrome with multivessel coronary artery disease from the CORALYS (Incidence and Predictors of Heart Failure After Acute Coronary Syndrome) registry were included. Incidence of first hospitalization for HF or cardiovascular death was the primary end point. Patients were stratified according to completeness of coronary revascularization. Of 14 699 patients in the CORALYS registry, 5054 presented with multivessel disease. One thousand four hundred seventy‐three (29.2%) underwent CR, while 3581 (70.8%) did not. Over 5 years follow‐up, CR was associated with a reduced incidence of the primary end point (adjusted hazard ratio [HR], 0.66 [95% CI, 0.51–0.85]), first HF hospitalization (adjusted HR, 0.67 [95% CI, 0.49–0.90]) along with all‐cause death and cardiovascular death alone (adjusted HR, 0.74 [95% CI, 0.56–0.97] and HR, 0.56 [95% CI, 0.38–0.84], respectively). The results were consistent in the propensity‐score matching population and in inverse probability treatment weighting analysis. The benefit of CR was consistent across acute coronary syndrome presentations (HR, 0.59 [95% CI, 0.39–0.89] for ST‐segment elevation myocardial infarction and HR, 0.71 [95% CI, 0.50–0.99] for non‐ST‐elevation acute coronary syndrome) and in patients with left ventricular ejection fraction >40% (HR, 0.52 [95% CI, 0.37–0.72]), while no benefit was observed in patients with left ventricular ejection fraction ≤40% (HR, 0.77 [95% CI, 0.37–1.10],
P
for interaction 0.04).

Conclusions

CR after acute coronary syndrome reduced the risk of first hospitalization for HF and cardiovascular death, as well as first HF hospitalization, and cardiovascular and overall death both in patients with ST‐segment elevation myocardial infarction and non‐ST‐elevation acute coronary syndrome.

Registration

URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT 04895176.